MRPL10

Across TCGA pan-cancer cohorts, MRPL10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRPL10 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MRPL10 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MRPL10 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where MRPL10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.627	0.425	.006	13	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	12	view →
HNSC	DFS	Tertile	All	0.953	1.000	.038	5	view →
PDAC	DFS	Quartile	All	0.475	0.317	.029	5	view →
LSCC	DFS	Median	II,III,IV	0.810	0.566	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRPL10–GBM (OS)

Open the GBM breakdown →